Twist Bioscience Corporation (TWST)
Automate Your Wheel Strategy on TWST
With Tiblio's Option Bot, you can configure your own wheel strategy including TWST - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TWST
- Rev/Share 5.8288
- Book/Share 7.3783
- PB 3.986
- Debt/Equity 0.1825
- CurrentRatio 4.514
- ROIC -0.3751
- MktCap 1762132501.0
- FreeCF/Share -1.0979
- PFCF -26.9065
- PE -9.1776
- Debt/Assets 0.1348
- DivYield 0
- ROE -0.4111
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TWST | Wolfe Research | -- | Outperform | -- | $60 | Dec. 13, 2024 |
News
Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced an expanded collaboration to enable Element's AVITI systems and Trinity flowcells with additional Twist library preparation and target enrichment workflows. “This collaboration bu.
Read More
Twist Bioscience: Expansion Efforts Continue To Face Challenges
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Negative
Twist Bioscience reported solid results in Q2, but management's downbeat tone on the earnings call suggest there are challenges ahead. Twist has also spun-out its data storage business, which will help to reduce cash burn. The transaction attributes a fairly modest valuation to the business, though. This comes after the recent struggles of the biopharma business and a royalty sale, which suggests the biopharma business hasn't created much value so far.
Read More
Twist Bioscience Corporation (TWST) Q2 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Twist Bioscience Corporation (NASDAQ:TWST ) Q2 2025 Earnings Conference Call April 5, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Matthew Sykes - Goldman Sachs Subbu Nambi - Guggenheim Securities Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Sung-Ji Nam - Scotiabank Thomas Peterson - Baird Brendan Smith - TD Cowen Operator Good day. …
Read More
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Twist Bioscience (TWST) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.79 per share a year ago.
Read More
Twist Bioscience Q2 Earnings Preview: Innovative Products, Not Enough Buyers
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Positive
Twist Bioscience has shown revenue growth from $54.4m in 2019 to potentially >$300m in 2024, but continues to post losses. Despite a diverse customer base and innovative synthetic DNA technology, Twist's stock has experienced sharp declines post-earnings on underwhelming financials. 2025 guidance shows ~20% revenue growth, but the market remains skeptical of Twist's ability to achieve profitability, leading to my downgrade from "Buy" to "Hold".
Read More
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
Read More
Twist Bioscience (TWST) Moves 6.6% Higher: Will This Strength Last?
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
About Twist Bioscience Corporation (TWST)
- IPO Date 2018-10-31
- Website https://www.twistbioscience.com
- Industry Medical - Diagnostics & Research
- CEO Dr. Emily Marine Leproust Ph.D.
- Employees 923